Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPC634 (CriPec docetaxel) in Platinum Resistant Ovarian Cancer
NCT03742713Phase 2Completed
- Sponsor
- Cristal Therapeutics
- Start
- Oct 2018
- Primary completion
- Dec 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of CPC634 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Cristal Therapeutics. Primary endpoint: Objective Response Rate. Started Oct 2018; status: completed.
02
Drugs
CPC634
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03742713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742713.